Molgramostim

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates
Name
Molgramostim
Accession Number
DB12525
Type
Biotech
Groups
Investigational
Biologic Classification
Protein Based Therapies
Other protein based therapies
Description

Molgramostim has been used in trials studying the treatment of Bronchiectasis, Cystic Fibrosis, Pulmonary Alveolar Proteinosis, Acute Respiratory Distress Syndrome, and Autoimmune Pulmonary Alveolar Proteinosis.

Protein chemical formula
Not Available
Protein average weight
Not Available
Sequences
Not Available
Synonyms
Not Available
Categories
UNII
B321AL142J
CAS number
99283-10-0

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
CyclophosphamideThe risk or severity of pulmonary toxicity can be increased when Molgramostim is combined with Cyclophosphamide.
Darbepoetin alfaThe risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Molgramostim.
ErythropoietinThe risk or severity of Thrombosis can be increased when Erythropoietin is combined with Molgramostim.
Methoxy polyethylene glycol-epoetin betaThe risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Molgramostim.
PeginesatideThe risk or severity of Thrombosis can be increased when Peginesatide is combined with Molgramostim.
VinblastineThe risk or severity of peripheral neuropathy can be increased when Molgramostim is combined with Vinblastine.
VincamineThe risk or severity of peripheral neuropathy can be increased when Molgramostim is combined with Vincamine.
VincristineThe risk or severity of peripheral neuropathy can be increased when Molgramostim is combined with Vincristine.
VindesineThe risk or severity of peripheral neuropathy can be increased when Molgramostim is combined with Vindesine.
VinflunineThe risk or severity of peripheral neuropathy can be increased when Molgramostim is combined with Vinflunine.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Substance
347911341
Wikipedia
Molgramostim
ATC Codes
L03AA03 — Molgramostim

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedTreatmentAcute Respiratory Distress Syndrome (ARDS) / Bronchiectasis / Cystic Fibrosis (CF) / Pulmonary Alveolar Proteinosis (PAP)1
2Active Not RecruitingTreatmentMycobacterium Infections, Nontuberculous1
2RecruitingTreatmentAcute Respiratory Distress Syndrome (ARDS)1
2RecruitingTreatmentCystic Fibrosis (CF) / Mycobacterium Infections, Nontuberculous1
2, 3Active Not RecruitingTreatmentAutoimmune Pulmonary Alveolar Proteinosis1
2, 3RecruitingTreatmentCutaneous Melanoma1
3CompletedTreatmentLeukemia Acute Myeloid Leukemia (AML)1
3Enrolling by InvitationTreatmentAutoimmune Pulmonary Alveolar Proteinosis1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Taxonomy

Description
Not Available
Kingdom
Organic Compounds
Super Class
Organic Acids
Class
Carboxylic Acids and Derivatives
Sub Class
Amino Acids, Peptides, and Analogues
Direct Parent
Peptides
Alternative Parents
Not Available
Substituents
Not Available
Molecular Framework
Not Available
External Descriptors
Not Available

Drug created on October 20, 2016 16:43 / Updated on December 02, 2019 09:27